


**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:


Claims 1-10. (Canceled).

11. (Currently amended) A method for treating or preventing ~~one or more gastrointestinal stromal tumors~~ an abnormal condition associated with an aberration in a signal transduction pathway mediated by a *c-kit* kinase in an organism, comprising administering to said organism a therapeutically effective amount of an indolinone compound of the following formula that modulates, *in vitro*, the catalytic activity of *c-kit* kinase:




wherein the abnormal condition is gastrointestinal tumor.

12. (Currently amended) A method for treating or preventing ~~mastocytosis~~ an abnormal condition associated with an aberration in a signal transduction pathway mediated by a *c-kit* kinase in an organism, comprising administering to said organism a therapeutically effective amount of an indolinone compound of the following formula that modulates, *in vitro*, the catalytic activity of *c-kit* kinase:




wherein the abnormal condition is mastocytosis.

13. (Currently amended) A method for treating or preventing ~~allergy-associated chronic rhinitis, inflammation or asthma~~ an abnormal condition associated with an aberration in a signal transduction pathway mediated by a *c-kit* kinase in an organism, comprising administering to said organism a therapeutically effective amount of an indolinone compound that modulates, *in vitro*, the catalytic activity of *c-kit* kinase selected from the group consisting of:




and



wherein the abnormal condition is allergy-associated chronic rhinitis, inflammation or asthma.

14. (Currently amended) A method for treating or preventing ~~one or more mast cell tumors~~ an abnormal condition associated with an aberration in a signal transduction pathway mediated by a *c-kit* kinase in an organism, comprising administering to said organism a therapeutically effective amount of an indolinone compound of the following formula that modulates, *in vitro*, the catalytic activity of *c-kit* kinase:



wherein the abnormal condition is mast cell tumor.

15. (Previously presented) The method of claim 11, wherein said organism is a mammal.

16. (Previously presented) The method of claim 15, wherein said mammal is selected from the group consisting of mouse, rat, rabbit, guinea pig, sheep, goat, cat, dog, monkey, human and ape.

17. (Previously presented) The method of claim 16, wherein said mammal is a human.
18. (Previously presented) 15. (Previously presented) The method of claim 12, wherein said organism is a mammal.
19. (Previously presented) The method of claim 18, wherein said mammal is selected from the group consisting of mouse, rat, rabbit, guinea pig, sheep, goat, cat, dog, monkey, human and ape.
20. (Previously presented) The method of claim 19, wherein said mammal is a dog.
21. (Previously presented) The method of claim 13, wherein said organism is a mammal.
22. (Previously presented) The method of claim 21, wherein said mammal is selected from the group consisting of mouse, rat, rabbit, guinea pig, sheep, goat, cat, dog, monkey, human and ape.
23. (Previously presented) The method of claim 22, wherein said mammal is a human.
24. (Previously presented) The method of claim 14, wherein said organism is a mammal.
25. (Previously presented) The method of claim 24, wherein said mammal is selected from the group consisting of mouse, rat, rabbit, guinea pig, sheep, goat, cat, dog, monkey, human and ape.
26. (Previously presented) The method of claim 25, wherein said mammal is a dog.